 The Food and Drug Administration approved Casunla, an Alzheimer's drug made by Eli Lilly. Casunla isn't a cure, but it slowed patients' cognitive decline in clinical trials. The drug removes clumps of protein in the brain called amyloid plaques that develop in people with Alzheimer's disease. Once they're gone, patients can stop taking the drug. A panel of experts advising the FDA unanimously backed the drug last month. Side effects can include headache as well as brain swelling and bleeding.